These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 32664750)
1. Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases. Li A; Mu X; He K; Wang P; Wang D; Liu C; Yu J Future Oncol; 2020 Oct; 16(30):2433-2444. PubMed ID: 32664750 [No Abstract] [Full Text] [Related]
2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096 [TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390 [TBL] [Abstract][Full Text] [Related]
4. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer. Yan X; Li G Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568 [TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. Tong YS; Tan J; Zhou XL; Song YQ; Song YJ J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030 [TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy. Cho A; Kranawetter B; Untersteiner H; Khalaveh F; Dorfer C; Rössler K; Zöchbauer-Müller S; Gatterbauer B; Hochmair MJ; Frischer JM World Neurosurg; 2021 Jul; 151():e324-e331. PubMed ID: 33878466 [TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864 [TBL] [Abstract][Full Text] [Related]
10. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. Gao Y; Zhang H; Li Y; Wang D; Ma Y; Chen Q Clin Chim Acta; 2018 Sep; 484():272-277. PubMed ID: 29860033 [TBL] [Abstract][Full Text] [Related]
11. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134 [TBL] [Abstract][Full Text] [Related]
12. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer. Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852 [TBL] [Abstract][Full Text] [Related]
13. Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer. Bayir D; Seber S; Yetisyigit T J Cancer Res Ther; 2020; 16(4):731-736. PubMed ID: 32930111 [TBL] [Abstract][Full Text] [Related]
14. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Guo W; Cai S; Zhang F; Shao F; Zhang G; Zhou Y; Zhao L; Tan F; Gao S; He J Thorac Cancer; 2019 Apr; 10(4):761-768. PubMed ID: 30734516 [TBL] [Abstract][Full Text] [Related]
15. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer? Sert F; Cosgun G; Yalman D; Ozkok S Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients With Stage I Non-Small Cell Lung Cancer Undergoing Complete Resection. Xia H; Sun Z; Deng L; Zhu D; Wang D Cancer Invest; 2016 Sep; 34(8):378-84. PubMed ID: 27558529 [TBL] [Abstract][Full Text] [Related]
17. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428 [TBL] [Abstract][Full Text] [Related]
18. Comparative Analysis of Inflammatory Indexes in Lung Cancer Patients With and Without Brain Metastases. Tamas F; Tamas CI; Suciu BA; Manu DR; Cehan AR; Balasa AF Cureus; 2024 May; 16(5):e60921. PubMed ID: 38910770 [TBL] [Abstract][Full Text] [Related]
19. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort. Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study. Takada K; Takamori S; Matsubara T; Haratake N; Akamine T; Kinoshita F; Ono Y; Wakasu S; Tanaka K; Oku Y; Oba T; Osoegawa A; Tagawa T; Takenoyama M; Shimokawa M; Oda Y; Mori M PLoS One; 2020; 15(11):e0241580. PubMed ID: 33137158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]